$0.55
(1.38%)
Add to watchlist
Create an alert
Stocks and Shares ISACastle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
Company Information
About this company
Key people
Derek J. Maetzold
President, Chief Executive Officer, Founder, Director
Frank Stokes
Chief Financial Officer
Kristen M. Oelschlager
Chief Operating Officer
Tobin W. Juvenal
Chief Commercial Officer
Daniel Mark Bradbury
Independent Chairman of the Board
Kimberlee S. Caple
Independent Director
G. Bradley Cole
Independent Director
Rodney Cotton
Independent Director
Ellen Goldberg
Independent Director
Click to see more
Key facts
- Shares in issue29.19m
- EPICCSTL
- ISINUS14843C1053
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$1.19bn
- Employees761
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.